Figure 1
Clinical characteristics of the cohort of patients with NSCLC (LUAD) analyzed in this study. (a) Workflow of the study (LUAD adenocarcinoma, SCC squamous cell carcinoma, ASC adenosquamous carcinoma, LCLC large cell lung carcinoma, NET neuroendocrine tumor, NET + ADC adeno-neuroendocrine carcinoma, MEC mucoepidermoid carcinoma). (b) Diagram of distribution of our patients’ cohort depending on the histological classification (LUAD: n = 81, SCC: n = 42, ASC: n = 2, LCLC: n = 2, NET: n = 6, NET + ADC: n = 3, MEC: n = 1). (c) Diagram of distribution of our patients’ cohort depending on the grading (G1: n = 6, G2: n = 33, G3: n = 39, unknown: n = 3). (d) Diagram of distribution of our patients’ cohort depending on the TNM classification (Stage I: n = 39, Stage II: n = 16, Stage III: n = 21, Stage IV: n = 5).
